U.S. Physical Therapy Management

Management criteria checks 3/4

U.S. Physical Therapy's CEO is Chris Reading, appointed in Nov 2004, has a tenure of 20.5 years. total yearly compensation is $3.64M, comprised of 26.8% salary and 73.2% bonuses, including company stock and options. directly owns 0.76% of the company’s shares, worth €8.25M. The average tenure of the management team and the board of directors is 5.8 years and 12.3 years respectively.

Key information

Chris Reading

Chief executive officer

US$3.6m

Total compensation

CEO salary percentage	26.79%
CEO tenure	20.5yrs
CEO ownership	0.8%
Management average tenure	5.8yrs
Board average tenure	12.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chris Reading's remuneration changed compared to U.S. Physical Therapy's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2025	n/a	n/a	US$33m
Dec 31 2024	US$4m	US$974k	US$28m
Sep 30 2024	n/a	n/a	US$14m
Jun 30 2024	n/a	n/a	US$16m
Mar 31 2024	n/a	n/a	US$18m
Dec 31 2023	US$3m	US$959k	US$18m
Sep 30 2023	n/a	n/a	US$24m
Jun 30 2023	n/a	n/a	US$26m
Mar 31 2023	n/a	n/a	US$28m
Dec 31 2022	US$2m	US$926k	US$29m
Sep 30 2022	n/a	n/a	US$39m
Jun 30 2022	n/a	n/a	US$38m
Mar 31 2022	n/a	n/a	US$37m
Dec 31 2021	US$4m	US$896k	US$31m
Sep 30 2021	n/a	n/a	US$31m
Jun 30 2021	n/a	n/a	US$30m
Mar 31 2021	n/a	n/a	US$32m
Dec 31 2020	US$3m	US$676k	US$32m
Sep 30 2020	n/a	n/a	US$30m
Jun 30 2020	n/a	n/a	US$31m
Mar 31 2020	n/a	n/a	US$29m
Dec 31 2019	US$3m	US$769k	US$31m
Sep 30 2019	n/a	n/a	US$30m
Jun 30 2019	n/a	n/a	US$23m
Mar 31 2019	n/a	n/a	US$18m
Dec 31 2018	US$3m	US$739k	US$17m

Compensation vs Market: Chris's total compensation ($USD3.64M) is above average for companies of similar size in the German market ($USD1.79M).

Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.

CEO

Chris Reading (60 yo)

20.5yrs

Tenure

US$3,636,676

Compensation

Mr. Christopher J. Reading, also known as Chris, has been the Chief Executive Officer of US Physical Therapy Inc. since November 1, 2004 and serves as its Chairman since May 21, 2024 and served as its Pres...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Christopher Reading	CEO & Chairman	20.5yrs	US$3.64m	0.76% € 8.2m
Eric Williams	President & COO	1yr	US$2.26m	0.18% € 1.9m
Carey Hendrickson	Chief Financial Officer	4.5yrs	US$1.63m	0.19% € 2.0m
Richard Binstein	Executive VP	14.3yrs	US$1.49m	0.13% € 1.4m
Graham Reeve	Chief Operating Officer - West	7.2yrs	US$1.85m	0.17% € 1.9m
Jake Martinez	Senior Vice President of Finance & Accounting	3.1yrs	no data	no data
Chadd Pence	Senior Vice President of Information Systems	no data	no data	no data
Jayne Pool	Senior VP & Chief Compliance Officer	no data	no data	no data
Jason Anderson	Vice President of Human Resources	no data	no data	no data

5.8yrs

Average Tenure

60yo

Average Age

Experienced Management: UPH's management team is seasoned and experienced (5.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Christopher Reading	CEO & Chairman	20.5yrs	US$3.64m	0.76% € 8.2m
Nancy Ham	Independent Director	2yrs	US$215.09k	0.0073% € 79.0k
Clayton Trier	Independent Director	20.3yrs	US$245.09k	0.042% € 456.4k
Bernard Harris	Lead Independent Director	19.8yrs	US$256.97k	0.11% € 1.2m
Kathleen Gilmartin	Independent Director	7yrs	US$235.09k	0.12% € 1.3m
Reginald Swanson	Independent Director	17.7yrs	US$225.09k	0.12% € 1.3m
Anne Motsenbocker	Independent Director	3.3yrs	US$215.09k	0.012% € 124.3k
Michael Mayrsohn	Director	less than a year	no data	0.12% € 1.3m

12.3yrs

Average Tenure

65yo

Average Age

Experienced Board: UPH's board of directors are seasoned and experienced ( 12.3 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/19 11:50
End of Day Share Price	2025/05/19 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

U.S. Physical Therapy, Inc. is covered by 14 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Michael Petusky	Barrington Research Associates, Inc.
Joanna Sylvia Gajuk	BofA Global Research
null null	Burkenroad Reports

U.S. Physical Therapy Management

Management criteria checks 3/4

Key information

Recent management updates

U.S. Physical Therapy, Inc., Annual General Meeting, May 20, 2025

President & COO recently sold €179k worth of stock

Chairman & CEO recently sold €196k worth of stock

Chief Operating Officer - East recently sold €242k worth of stock

U.S. Physical Therapy, Inc., Annual General Meeting, May 21, 2024

Chief Operating Officer - West recently sold €253k worth of stock

Recent updates

U.S. Physical Therapy, Inc. Declares Quarterly Dividend, Payable on June 13, 2025

U.S. Physical Therapy, Inc. to Report Q1, 2025 Results on May 07, 2025

U.S. Physical Therapy, Inc., Annual General Meeting, May 20, 2025

U.S. Physical Therapy, Inc. Raises Quarterly Dividend and Declares Quarterly Dividend for the First Quarter of 2025, Payable on April 11, 2025

U.S. Physical Therapy, Inc. to Report Q4, 2024 Results on Feb 27, 2025

President & COO recently sold €179k worth of stock

Third quarter dividend of US$0.44 announced

Third quarter 2024 earnings released: EPS: US$0.39 (vs US$0.51 in 3Q 2023)

U.S. Physical Therapy, Inc. Declares Quarterly Dividend, Payable on December 6, 2024

U.S. Physical Therapy, Inc. to Report Q3, 2024 Results on Nov 05, 2024

U.S. Physical Therapy, Inc. Declares Quarterly Dividend, Payable on September 13, 2024

U.S. Physical Therapy, Inc. announced delayed 10-Q filing

U.S. Physical Therapy, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Now 21% undervalued after recent price drop

Chairman & CEO recently sold €196k worth of stock

Chief Operating Officer - East recently sold €242k worth of stock

First quarter dividend of US$0.44 announced

First quarter 2024 earnings released: EPS: US$0.54 (vs US$0.58 in 1Q 2023)

U.S. Physical Therapy, Inc., Annual General Meeting, May 21, 2024

Chief Operating Officer - West recently sold €253k worth of stock

Fourth quarter dividend of US$0.44 announced

New minor risk - Profit margin trend

U.S. Physical Therapy, Inc. Increases Quarterly Dividend, Payable on April 5, 2024

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: US$1.99 (vs US$2.25 in FY 2022)

Now 21% undervalued

U.S. Physical Therapy, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Now 21% undervalued after recent price drop

Third quarter 2023 earnings released: EPS: US$0.62 (vs US$0.72 in 3Q 2022)

U.S. Physical Therapy, Inc. Declares Quarterly Dividend, Payable on December 8, 2023

U.S. Physical Therapy, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Chief Operating Officer - West recently sold €413k worth of stock

Second quarter 2023 earnings released: EPS: US$0.80 (vs US$0.87 in 2Q 2022)

U.S. Physical Therapy, Inc. Declares Quarterly Dividend, Payable on September 8, 2023

U.S. Physical Therapy, Inc. (NYSE:USPH) acquired a 70% stake in U.S. Physical Therapy, Inc. (NYSE:USPH) for $2.1 million.

U.S. Physical Therapy, Inc. to Report Q2, 2023 Results on Aug 08, 2023

U.S. Physical Therapy, Inc. (NYSE:USPH) acquired 75% interest in Physical therapy practice with four clinics for $3.1 million

U.S. Physical Therapy, Inc. has completed a Follow-on Equity Offering in the amount of $150.00003 million.

U.S. Physical Therapy, Inc. Elects Nancy Ham to the Board of Directors

Upcoming dividend of US$0.43 per share at 1.6% yield

U.S. Physical Therapy Declares Quarterly Dividend, Payable on June 9, 2023

First quarter 2023 earnings released: EPS: US$0.57 (vs US$0.67 in 1Q 2022)

Independent Director recently sold €439k worth of stock

Executive VP recently sold €87k worth of stock

Upcoming dividend of US$0.43 per share at 1.7% yield

Full year 2022 earnings released: EPS: US$2.25 (vs US$2.42 in FY 2021)

U.S. Physical Therapy, Inc. to Report Q4, 2022 Results on Feb 22, 2023

Independent Director recently sold €573k worth of stock

President recently sold €858k worth of stock

U.S. Physical Therapy, Inc. (NYSE:USPH) acquired 80% stake in Thirteen-clinic physical therapy practice from practice’s owners for $25 million.

Insufficient new directors

Upcoming dividend of US$0.41 per share

Chief Operating Officer - West recently sold €162k worth of stock

Now 23% undervalued after recent price drop

Third quarter 2022 earnings released: EPS: US$0.73 (vs US$0.66 in 3Q 2021)

U.S. Physical Therapy, Inc. Provides Operating Guidance for 2022

U.S. Physical Therapy, Inc. to Report Q3, 2022 Results on Nov 03, 2022

U.S. Physical Therapy, Inc. (NYSE:USPH) acquired 80% stake in Two-Clinic Physical Therapy Practice for $4.2 million.

Director recently bought €78k worth of stock

U.S. Physical Therapy, Inc. (NYSE:USPH) acquired a 70% stake in six-clinic physical therapy practice in West Virginia and Pennsylvania for $3.5 million.

Independent Director recently bought €82k worth of stock

Independent Director recently bought €54k worth of stock

Second quarter 2022 earnings released: EPS: US$0.86 (vs US$0.82 in 2Q 2021)

U.S. Physical Therapy, Inc. Declares Quarterly Dividend, Payable on September 16, 2022

U.S. Physical Therapy, Inc. to Report Q2, 2022 Results on Aug 04, 2022

First quarter 2022 earnings released: EPS: US$0.68 (vs US$0.21 in 1Q 2021)

U.S. Physical Therapy, Inc. Declares Quarterly Dividend, Payable on June 14, 2022

Insufficient new directors

U.S. Physical Therapy, Inc. to Report Q1, 2022 Results on May 05, 2022